176 related articles for article (PubMed ID: 26732684)
41. Ring-ing in the Future: Participant and Male Partner Perspectives Regarding Future Use of the Dapivirine Vaginal Ring for HIV Prevention.
Reddy K; Mathebula F; Katz A; Luecke E; Tenza S; Palanee-Phillips T; Garcia M; Mansoor LE; Naidoo S; Morar N; Chitukuta M; Tsidya M; Montgomery ET;
AIDS Behav; 2022 Jun; 26(6):1923-1932. PubMed ID: 35064389
[TBL] [Abstract][Full Text] [Related]
42. Microbicides for prevention of HIV infection: clinical efficacy trials.
Abdool Karim SS; Baxter C
Curr Top Microbiol Immunol; 2014; 383():97-115. PubMed ID: 23695725
[TBL] [Abstract][Full Text] [Related]
43. Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women.
Bunge KE; Levy L; Szydlo DW; Zhang J; Gaur AH; Reirden D; Mayer KH; Futterman D; Hoesley C; Hillier SL; Marzinke MA; Hendrix CW; Gorbach PM; Wilson CM; Soto-Torres L; Kapogiannis B; Nel A; Squires KE;
J Acquir Immune Defic Syndr; 2020 Feb; 83(2):135-139. PubMed ID: 31929401
[TBL] [Abstract][Full Text] [Related]
44. Reasons for nonadherence to the dapivirine vaginal ring: narrative explanations of objective drug-level results.
Montgomery ET; Stadler J; Naidoo S; Katz AWK; Laborde N; Garcia M; Reddy K; Mansoor LE; Etima J; Zimba C; Chitukuta M; Soto-Torres L
AIDS; 2018 Jul; 32(11):1517-1525. PubMed ID: 29957723
[TBL] [Abstract][Full Text] [Related]
45. Impact of ring size and drug loading on the pharmacokinetics of a combination dapivirine-darunavir vaginal ring in cynomolgus macaques.
Murphy DJ; Desjardins D; Boyd P; Dereuddre-Bosquet N; Stimmer L; Caldwell A; Le Grand R; Kelly C; van Roey J; Malcolm RK
Int J Pharm; 2018 Oct; 550(1-2):300-308. PubMed ID: 30153490
[TBL] [Abstract][Full Text] [Related]
46. Development of a multi-layered vaginal tablet containing dapivirine, levonorgestrel and acyclovir for use as a multipurpose prevention technology.
McConville C; Major I; Devlin B; Brimer A
Eur J Pharm Biopharm; 2016 Jul; 104():171-9. PubMed ID: 27163243
[TBL] [Abstract][Full Text] [Related]
47. A modified SILCS contraceptive diaphragm for long-term controlled release of the HIV microbicide dapivirine.
Major I; Boyd P; Kilbourne-Brook M; Saxon G; Cohen J; Malcolm RK
Contraception; 2013 Jul; 88(1):58-66. PubMed ID: 23177261
[TBL] [Abstract][Full Text] [Related]
48. Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception.
Balkus JE; Palanee-Phillips T; Reddy K; Siva S; Harkoo I; Nakabiito C; Kintu K; Nair G; Chappell C; Kiweewa FM; Kabwigu S; Naidoo L; Jeenarain N; Marzinke M; Soto-Torres L; Brown ER; Baeten JM
J Acquir Immune Defic Syndr; 2017 Oct; 76(2):e47-e51. PubMed ID: 28542081
[TBL] [Abstract][Full Text] [Related]
49. Formulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV prevention.
Akil A; Agashe H; Dezzutti CS; Moncla BJ; Hillier SL; Devlin B; Shi Y; Uranker K; Rohan LC
Pharm Res; 2015 Feb; 32(2):458-68. PubMed ID: 25079391
[TBL] [Abstract][Full Text] [Related]
50. In Silico and in Vitro Screening for P-Glycoprotein Interaction with Tenofovir, Darunavir, and Dapivirine: An Antiretroviral Drug Combination for Topical Prevention of Colorectal HIV Transmission.
Swedrowska M; Jamshidi S; Kumar A; Kelly C; Rahman KM; Forbes B
Mol Pharm; 2017 Aug; 14(8):2660-2669. PubMed ID: 28648081
[TBL] [Abstract][Full Text] [Related]
51. Clinical testing of antiretroviral drugs as future prevention against vaginal and rectal transmission of HIV infection - a review of currently available results.
Vysloužil J; Kubová K; Tkadlečková VN; Vetchý D
Acta Pharm; 2019 Sep; 69(3):297-319. PubMed ID: 31259738
[TBL] [Abstract][Full Text] [Related]
52. Recent work on vaginal rings containing antiviral agents for HIV prevention.
Spence P; Bhatia Garg A; Woodsong C; Devin B; Rosenberg Z
Curr Opin HIV AIDS; 2015 Jul; 10(4):264-70. PubMed ID: 26049952
[TBL] [Abstract][Full Text] [Related]
53. Acceptability of the dapivirine vaginal ring for HIV-1 prevention among women reporting engagement in transactional sex.
Browne EN; Torjesen K; Mirembe BG; Palanee-Phillips T; Jeenarain N; Chitukuta M; Stoner MCD; Mansoor LE; Reddy K; Tauya TT; Naidoo L; Siva S; Richardson B; Dadabhai S; Seyama L; Soto-Torres L; van der Straten A;
AIDS Care; 2024 Jan; 36(1):80-86. PubMed ID: 37066990
[TBL] [Abstract][Full Text] [Related]
54. Does the Ring Work? Perceptions and Understanding of the Efficacy of a Dapivirine Vaginal Ring for HIV Prevention Amongst Women in a Placebo-Controlled Trial.
Etima J; Katz AWK; Duby Z; Garcia M; Palanee-Phillips T; Reddy K; Mathebula F; Zimba C; Mansoor LE; Singh D; Manengamambo E; Naidoo S; Soto-Torres L; Montgomery ET;
AIDS Behav; 2022 May; 26(5):1597-1606. PubMed ID: 34727272
[TBL] [Abstract][Full Text] [Related]
55. Towards a dapivirine and levonorgestrel multipurpose vaginal ring: Investigations into the reaction between levonorgestrel and addition-cure silicone elastomers.
Dallal Bashi YH; McCoy CF; Murphy DJ; Boyd P; Spence P; Kleinbeck K; Devlin B; Malcolm RK
Int J Pharm; 2019 Oct; 569():118574. PubMed ID: 31352053
[TBL] [Abstract][Full Text] [Related]
56. Influence of dapivirine vaginal ring use on cervicovaginal immunity and functional microbiome in adolescent girls.
Farr Zuend C; Noël-Romas L; Hoger S; McCorriser S; Westmacott G; Marrazzo J; Hillier SL; Dezzutti C; Squires K; Bunge KE; Burgener A
AIDS; 2021 Mar; 35(3):369-380. PubMed ID: 33181534
[TBL] [Abstract][Full Text] [Related]
57. Expression of Genes for Drug Transporters in the Human Female Genital Tract and Modulatory Effect of Antiretroviral Drugs.
Hijazi K; Cuppone AM; Smith K; Stincarelli MA; Ekeruche-Makinde J; De Falco G; Hold GL; Shattock R; Kelly CG; Pozzi G; Iannelli F
PLoS One; 2015; 10(6):e0131405. PubMed ID: 26102284
[TBL] [Abstract][Full Text] [Related]
58. Pharmaceutical development of microbicide drug products.
Friend DR
Pharm Dev Technol; 2010 Dec; 15(6):562-81. PubMed ID: 20017601
[TBL] [Abstract][Full Text] [Related]
59. Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS.
Gupta SK; Nutan
HIV AIDS (Auckl); 2013 Oct; 5():295-307. PubMed ID: 24174883
[TBL] [Abstract][Full Text] [Related]
60. Assessment of risk compensation following use of the dapivirine vaginal ring in southwestern Uganda.
Kusemererwa S; Abaasa A; Kabarambi A; Onyango M; Mugisha JO
Sex Transm Infect; 2022 Feb; 98(1):32-37. PubMed ID: 33542153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
